Physician profile
Jennifer Fields
NPI 1992188023
$1,161.00
in general payments reported to CMS, 2019-2025
12 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $78.71 · 2023: $474 · 2024: $95.55 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.99 | 2023-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $148.93 | 2023-2025 | Mitraclip, Navitor |
| Amgen INC. | $122.58 | 2021-2023 | Repatha |
| Organogenesis INC. | $120.55 | 2021-2023 | Puraply |
| Merck Sharp & Dohme LLC | $107.97 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.23 | 2024 | Lifevest |
| Cvrx, INC. | $35.11 | 2023 | Barostim Neo System |
| Abbvie INC. | $23.97 | 2024 | |
| Boston Scientific Corporation | $18.59 | 2023 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $15.85 | 2021 | |
| Pfizer INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.